Crystal Structures of the Human Dysferlin Inner DysF Domain

Overview

Journal BMC Struct Biol

Publisher Biomed Central

Specialties Biochemistry
Molecular Biology

Date 2014 Jan 21

PMID 24438169

Citations 25

Authors

Altin Sula

Ambrose R Cole

Corin Yeats

Christine Orengo

Nicholas H Keep

Affiliations

Soon will be listed here.

Abstract

Background: Mutations in dysferlin, the first protein linked with the cell membrane repair mechanism, causes a group of muscular dystrophies called dysferlinopathies. Dysferlin is a type two-anchored membrane protein, with a single C terminal trans-membrane helix, and most of the protein lying in cytoplasm. Dysferlin contains several C2 domains and two DysF domains which are nested one inside the other. Many pathogenic point mutations fall in the DysF domain region.

Results: We describe the crystal structure of the human dysferlin inner DysF domain with a resolution of 1.9 Ångstroms. Most of the pathogenic mutations are part of aromatic/arginine stacks that hold the domain in a folded conformation. The high resolution of the structure show that these interactions are a mixture of parallel ring/guanadinium stacking, perpendicular H bond stacking and aliphatic chain packing.

Conclusions: The high resolution structure of the Dysferlin DysF domain gives a template on which to interpret in detail the pathogenic mutations that lead to disease.

Citing Articles

Utilizing Spermatogenesis and Fertilization Mutants as a Model for Human Disease.

Perez S, Augustineli H, Marcello M J Dev Biol. 2025; 13(1).

PMID: 39982357 PMC: 11843878. DOI: 10.3390/jdb13010004.

Antisense oligonucleotide-mediated exon 27 skipping restores dysferlin function in dysferlinopathy patient-derived muscle cells.

Anwar S, Roshmi R, Woo S, Haque U, Arthur Lee J, Duddy W Mol Ther Nucleic Acids. 2025; 36(1):102443.

PMID: 39967852 PMC: 11834094. DOI: 10.1016/j.omtn.2024.102443.

Limb-Girdle Muscular Dystrophies (LGMD): Clinical features, diagnosis and genetic variability through next generation sequencing.

Mathur P, Kaur A, Vijay U, Gupta A, Agarwal K, Agrawal L Glob Med Genet. 2025; 12(1):100035.

PMID: 39925440 PMC: 11800303. DOI: 10.1016/j.gmg.2024.100035.

Cryo-EM structures of the membrane repair protein dysferlin.

Huang H, Grandinetti G, Heissler S, Chinthalapudi K Nat Commun. 2024; 15(1):9650.

PMID: 39511170 PMC: 11544258. DOI: 10.1038/s41467-024-53773-6.

Clinical description of a homozygous Lys 1169* variant in the DYSF gene associated with autosomal recessive Miyoshi muscular dystrophy type 1: A familial case report.

Aguirre A, Romero V Heliyon. 2024; 10(15):e35333.

PMID: 39170343 PMC: 11336582. DOI: 10.1016/j.heliyon.2024.e35333.

References

Tagawa K, Ogawa M, Kawabe K, Yamanaka G, Matsumura T, Goto K . Protein and gene analyses of dysferlinopathy in a large group of Japanese muscular dystrophy patients. J Neurol Sci. 2003; 211(1-2):23-8. DOI: 10.1016/s0022-510x(03)00041-8. View

Letunic I, Doerks T, Bork P . SMART 7: recent updates to the protein domain annotation resource. Nucleic Acids Res. 2011; 40(Database issue):D302-5. PMC: 3245027. DOI: 10.1093/nar/gkr931. View

Cagliani R, Magri F, Toscano A, Merlini L, Fortunato F, Lamperti C . Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies. Hum Mutat. 2005; 26(3):283. DOI: 10.1002/humu.9364. View

Evans P . An introduction to data reduction: space-group determination, scaling and intensity statistics. Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 4):282-92. PMC: 3069743. DOI: 10.1107/S090744491003982X. View

Takahashi T, Aoki M, Tateyama M, Kondo E, Mizuno T, Onodera Y . Dysferlin mutations in Japanese Miyoshi myopathy: relationship to phenotype. Neurology. 2003; 60(11):1799-804. DOI: 10.1212/01.wnl.0000068333.43005.12. View

Murshudov G, Vagin A, Dodson E . Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997; 53(Pt 3):240-55. DOI: 10.1107/S0907444996012255. View

Fanin M, Nascimbeni A, Angelini C . Muscle protein analysis in the detection of heterozygotes for recessive limb girdle muscular dystrophy type 2B and 2E. Neuromuscul Disord. 2006; 16(11):792-9. DOI: 10.1016/j.nmd.2006.06.010. View

Cho H, Sung D, Kim E, Yoon C, Ki C, Kim J . Clinical and genetic analysis of Korean patients with Miyoshi myopathy: identification of three novel mutations in the DYSF gene. J Korean Med Sci. 2006; 21(4):724-7. PMC: 2729898. DOI: 10.3346/jkms.2006.21.4.724. View

Doreleijers J, Sousa da Silva A, Krieger E, Nabuurs S, Spronk C, Stevens T . CING: an integrated residue-based structure validation program suite. J Biomol NMR. 2012; 54(3):267-83. PMC: 3483101. DOI: 10.1007/s10858-012-9669-7. View

10.

Cagliani R, Fortunato F, Giorda R, Rodolico C, Bonaglia M, Sironi M . Molecular analysis of LGMD-2B and MM patients: identification of novel DYSF mutations and possible founder effect in the Italian population. Neuromuscul Disord. 2003; 13(10):788-95. DOI: 10.1016/s0960-8966(03)00133-0. View

11.

De Luna N, Gallardo E, Soriano M, Dominguez-Perles R, de la Torre C, Rojas-Garcia R . Absence of dysferlin alters myogenin expression and delays human muscle differentiation "in vitro". J Biol Chem. 2006; 281(25):17092-17098. DOI: 10.1074/jbc.M601885200. View

12.

Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C . Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet. 1998; 20(1):31-6. DOI: 10.1038/1682. View

13.

Flocco M, Mowbray S . Planar stacking interactions of arginine and aromatic side-chains in proteins. J Mol Biol. 1994; 235(2):709-17. DOI: 10.1006/jmbi.1994.1022. View

14.

Xu L, Pallikkuth S, Hou Z, Mignery G, Robia S, Han R . Dysferlin forms a dimer mediated by the C2 domains and the transmembrane domain in vitro and in living cells. PLoS One. 2011; 6(11):e27884. PMC: 3215728. DOI: 10.1371/journal.pone.0027884. View

15.

Savitsky P, Bray J, Cooper C, Marsden B, Mahajan P, Burgess-Brown N . High-throughput production of human proteins for crystallization: the SGC experience. J Struct Biol. 2010; 172(1):3-13. PMC: 2938586. DOI: 10.1016/j.jsb.2010.06.008. View

16.

Keegan R, Winn M . MrBUMP: an automated pipeline for molecular replacement. Acta Crystallogr D Biol Crystallogr. 2007; 64(Pt 1):119-24. PMC: 2394800. DOI: 10.1107/S0907444907037195. View

17.

Therrien C, Di Fulvio S, Pickles S, Sinnreich M . Characterization of lipid binding specificities of dysferlin C2 domains reveals novel interactions with phosphoinositides. Biochemistry. 2009; 48(11):2377-84. DOI: 10.1021/bi802242r. View

18.

Patel P, Harris R, Geddes S, Strehle E, Watson J, Bashir R . Solution structure of the inner DysF domain of myoferlin and implications for limb girdle muscular dystrophy type 2b. J Mol Biol. 2008; 379(5):981-90. DOI: 10.1016/j.jmb.2008.04.046. View

19.

Cuff A, Sillitoe I, Lewis T, Clegg A, Rentzsch R, Furnham N . Extending CATH: increasing coverage of the protein structure universe and linking structure with function. Nucleic Acids Res. 2010; 39(Database issue):D420-6. PMC: 3013636. DOI: 10.1093/nar/gkq1001. View

20.

Kesari A, Fukuda M, Knoblach S, Bashir R, Nader G, Rao D . Dysferlin deficiency shows compensatory induction of Rab27A/Slp2a that may contribute to inflammatory onset. Am J Pathol. 2008; 173(5):1476-87. PMC: 2570137. DOI: 10.2353/ajpath.2008.080098. View